论文信息 - Risk in drug trials - 字舞流文

Risk in drug trials

J. Sugarman | C. Levine

[1] MJH Kenter,et al. Establishing risk of human experimentation with drugs: lessons from TGN1412 , 2006, The Lancet.

[2] A. Sharpe,et al. T-cell costimulation--biology, therapeutic potential, and challenges. , 2006, The New England journal of medicine.

[3] Nicki Panoskaltsis,et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[4] J. Drazen. Volunteers at risk. , 2006, The New England journal of medicine.

[5] S. Hansen,et al. TGN1412: scrutinizing preclinical trials of antibody-based medicines , 2006, Nature.

[6] J. Löwer,et al. TGN1412—a regulator's perspective , 2006, Nature Biotechnology.

[7] S. Balkow,et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. , 2005, Blood.

[8] C. Grady,et al. Special Scrutiny: A Targeted Form of Research Protocol Review , 2004, Annals of Internal Medicine.

[9] C. King,et al. Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules , 2001, Immunogenetics.